Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
New data shows that Novo Nordisk's (NVO) obesity therapy, Wegovy, has reduced kidney-related events by 22% in obese or ...
The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23 ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Die Medikamente zur Gewichtsreduktion von Eli Lilly und Novo Nordisk sind in aller Munde. Dabei steht der nächste Blockbuster ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Der Pharmakonzern Novo Nordisk hat im ersten Quartal dank der hohen Nachfrage nach seinen Appetitzüglern einen Umsatz- und Gewinnsprung verzeichnet. So stieg der Umsatz um 22 Prozent auf 65,35 ...
London, 02. Mai (Reuters) - Der dänische Pharmakonzern Novo Nordisk profitiert weiter vom Boom seiner Abnehmmedikamente und hat die Prognose für 2024 angehoben. Für den Umsatz rechnet der ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.